美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Biofrontera Inc Warrant

0.0412

-0.0248-37.58%

成交量：1,762.00

成交额：89.12

市值：43.95万

市盈率：-0.02

高：0.0640

开：0.0640

低：0.0412

收：0.0660

52周最高：0.2770

52周最低：0.0251

股本：1,066.84万

流通股本：1,066.84万

量比：5.09

换手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-1.8444

净资产收益率：-325.31%

总资产收益率：-35.18%

市净率：0.03

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

Biofrontera Inc宣布完成用于躯干及四肢光化性角化病的Ameluz®一期药代动力学研究数据库锁定

Biofrontera宣布FDA受理Ameluz®光动力疗法治疗浅表基底细胞癌的补充新药申请

Biofrontera公布Ameluz®光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究积极结果，达到主要终点

Biofrontera Inc宣布两项临床研究数据库锁定，助力关键数据与监管里程碑达成

Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让

Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元

Biofrontera Inc宣布Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究最后一名患者完成试验

Biofrontera Inc宣布Ameluz®（盐酸氨基乙酰丙酸）10%外用凝胶治疗中重度寻常痤疮的2B期研究完成最后一名患者出组

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BFRIW/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BFRIW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","market":"US","secType":"STK","nameCN":"Biofrontera Inc Warrant","latestPrice":0.0412,"timestamp":1772744400000,"preClose":0.066,"halted":0,"volume":1762,"delay":0,"changeRate":-0.3757575757575758,"floatShares":10668438,"shares":10668438,"eps":-1.8444,"marketStatus":"盘前交易","change":-0.0248,"latestTime":"03-06 08:20:40 EST","open":0.064,"high":0.064,"low":0.0412,"amount":89.122648,"amplitude":0.345455,"askPrice":0,"askSize":0,"bidPrice":0.037,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.8444,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772807400000},"marketStatusCode":1,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":0.0412,"volumeRatio":5.089545380547214},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","floatShares":10668438,"roa":"-35.18%","roe":"-325.31%","lyrEps":0,"volumeRatio":5.089545380547214,"shares":10668438,"dividePrice":0,"high":0.064,"amplitude":0.345455,"preClose":0.066,"low":0.0412,"week52Low":0.0251,"pbRate":"0.03","psRate":"0.02","week52High":0.277,"institutionHeld":0,"latestPrice":0.0412,"committee":1,"eps":-1.8444,"divideRate":0,"volume":1762,"delay":0,"ttmEps":-1.8444,"open":0.064,"prevYearClose":0.09,"prevWeekClose":0.0679,"prevMonthClose":0.0679,"prevQuarterClose":0.09,"fiveDayClose":0.0679,"twentyDayClose":0.063,"sixtyDayClose":0.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BFRIW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BFRIW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BFRIW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BFRIW\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1184834707","title":"Biofrontera Inc宣布完成用于躯干及四肢光化性角化病的Ameluz®一期药代动力学研究数据库锁定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184834707","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184834707?lang=zh_cn&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337729,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（纳斯达克代码：BFRI）近日宣布，其针对躯干及四肢光化性角化病的Ameluz®药物一期药代动力学研究已完成数据库锁定。这一关键步骤标志着该临床试验数据收集阶段的正式结束，为后续的数据分析和结果评估奠定了坚实基础。公司表示，此项研究的推进将进一步丰富Ameluz®在皮肤疾病治疗领域的临床应用数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"1161002689","title":"Biofrontera宣布FDA受理Ameluz®光动力疗法治疗浅表基底细胞癌的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1161002689","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161002689?lang=zh_cn&edition=fundamental","pubTime":"2026-02-11 22:16","pubTimestamp":1770819389,"startTime":"0","endTime":"0","summary":"Biofrontera Inc（简称Biofrontera）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对Ameluz®光动力疗法（PDT）用于治疗浅表基底细胞癌（sBCC）的补充新药申请（sNDA）。这一重要进展标志着该药物在拓展适应症方面迈出了关键一步，为患者提供了潜在的新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"1179752893","title":"Biofrontera公布Ameluz®光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究积极结果，达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1179752893","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179752893?lang=zh_cn&edition=fundamental","pubTime":"2026-02-09 22:16","pubTimestamp":1770646572,"startTime":"0","endTime":"0","summary":"Biofrontera Inc (NASDAQ: BFRI) 宣布，其用于治疗四肢、颈部和躯干光化性角化病的Ameluz®光动力疗法在三期临床研究中取得积极结果，成功达到了主要研究终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"1141539493","title":"Biofrontera Inc宣布两项临床研究数据库锁定，助力关键数据与监管里程碑达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1141539493","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141539493?lang=zh_cn&edition=fundamental","pubTime":"2026-01-08 21:50","pubTimestamp":1767880249,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布，其两项临床研究已完成数据库锁定，此举将为关键数据的获取及后续监管里程碑的实现提供重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"1137380408","title":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让","url":"https://stock-news.laohu8.com/highlight/detail?id=1137380408","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137380408?lang=zh_cn&edition=fundamental","pubTime":"2025-12-18 21:50","pubTimestamp":1766065819,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 完成 Ameluz® 和 Rhodoled® 的 FDA 批准转移及相关知识产权组合的转让","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"1160367010","title":"Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160367010","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160367010?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 21:02","pubTimestamp":1762520543,"startTime":"0","endTime":"0","summary":"Biofrontera Inc. 宣布将 Xepi® 抗生素乳膏的许可出售给 Pelthos Therapeutics Inc.，最高可达 1000 万美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"1185650039","title":"Biofrontera Inc宣布Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法治疗四肢、颈部和躯干光化性角化病三期研究最后一名患者完成试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1185650039","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185650039?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 22:30","pubTimestamp":1758033054,"startTime":"0","endTime":"0","summary":"Biofrontera Inc近日宣布，其针对Ameluz®(盐酸氨基酮戊酸)外用凝胶10%光动力疗法的三期临床研究已完成最后一名患者的试验。该研究旨在评估这种光动力疗法治疗四肢、颈部和躯干部位光化性角化病的有效性和安全性。\n随着最后一名受试者完成研究流程，这项重要的三期临床试验正式结束患者招募和治疗阶段。这标志着Biofrontera Inc在推进其Ameluz®产品用于治疗特定部位光化性角化病方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"1182774938","title":"Biofrontera Inc宣布Ameluz®（盐酸氨基乙酰丙酸）10%外用凝胶治疗中重度寻常痤疮的2B期研究完成最后一名患者出组","url":"https://stock-news.laohu8.com/highlight/detail?id=1182774938","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182774938?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 20:25","pubTimestamp":1756124753,"startTime":"0","endTime":"0","summary":"Biofrontera Inc宣布Ameluz®（盐酸氨基乙酰丙酸）10%外用凝胶治疗中重度寻常痤疮的2B期研究完成最后一名患者出组","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}